MALT1 and melanoma: Similar to JNK/AP1, NF-κB has been characterized as potential target for melanoma.54, 65, 66 Nonetheless, neither JNK/c-Jun nor NF-κB targeted inhibition has been translated into clinical care for melanoma due to poor pharmacological kinetics or lack of specificity.67, 68, 69 Presumably, MALT1 can be explored as an alternative molecular target.